Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 February, 2019 06:00 IST
Suven Life Sciences secures 2 overseas product patents
Source: IRIS | 06 Nov, 2018, 10.54AM
Comments  |  Post Comment

Suven Life Sciences announces today that the grant of one product patent from Israel and one product patent from Japan corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2034 respectively.

The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' said Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 3.25, or 1.35%, to trade at Rs 244.00. The total volume of shares traded was 15,444 at the BSE (10.42 a.m., Tuesday).



Suven Life Sciences Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Aarti Industries signs USD 125 mn multi-year deal - 20-Feb-2019 10:53
Glenmark to present data on Ryaltris at AAAAI 2019 - 20-Feb-2019 10:48
Fitch rates STFC's USD senior secured bonds 'BB+(EXP)' - 20-Feb-2019 10:33
ABB bags train technologies order worth Rs 2.70 bn - 20-Feb-2019 10:30
Cipla, Wellthy Therapeutics announce partnership to offer digital therapeutics - 19-Feb-2019 10:58
Glenmark Pharma receives ANDA approval for Clobetasol propionate foam - 18-Feb-2019 10:45
L&T Construction secures contract for design and construction of major airport - 18-Feb-2019 10:42
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer